GURUFOCUS.COM » STOCK LIST » Technology » Software » Firefly Neuroscience Inc (NAS:AIFF) » Definitions » PensionAndRetirementBenefit

AIFF (Firefly Neuroscience) PensionAndRetirementBenefit : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Firefly Neuroscience PensionAndRetirementBenefit?

Firefly Neuroscience's PensionAndRetirementBenefit for the quarter that ended in Mar. 2025 was $0.00 Mil.


Firefly Neuroscience PensionAndRetirementBenefit Historical Data

The historical data trend for Firefly Neuroscience's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firefly Neuroscience PensionAndRetirementBenefit Chart

Firefly Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24
PensionAndRetirementBenefit
- - - -

Firefly Neuroscience Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Firefly Neuroscience PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Firefly Neuroscience Business Description

Traded in Other Exchanges
N/A
Address
1100 Military Road, Kenmore, NY, USA, 14217
Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The Company has one reportable segment: the BNA platform. The Company derives revenue from North America.